MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease

ABSTRACT

Compositions and methods for diagnosing high-grade cervical disease in a patient sample are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MCM6 or MCM7. Monoclonal antibodies having the binding characteristics of an MCM6 or MCM7 antibody of the invention are further provided. Hybridoma cell lines that produce an MCM6 or MCM7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in practicing methods for diagnosing high-grade cervical disease comprising detecting overexpression of MCM6, MCM7, or both MCM6 and MCM7 in a cervical sample from a patient. Kits for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MCM6 or an MCM7 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application Ser.No. 60/751,495, filed Dec. 19, 2005, which is incorporated herein byreference in its entirety.

FIELD OF THE INVENTION

The invention relates to antibodies capable of binding to MCM6 or MCM7and methods of using these antibodies, particularly in the diagnosis ofcervical disease.

BACKGROUND OF THE INVENTION

Carcinoma of the cervix is the second most common neoplasm in women,accounting for approximately 12% of all female cancers and causingapproximately 250,000 deaths per year. Baldwin et al. (2003) NatureReviews Cancer 3:1-10. In many developing countries where mass screeningprograms are not available, the clinical problem is more serious.Cervical cancer in these countries is the number one cause of cancerdeaths in women.

The majority of cases of cervical cancer represent squamous cellcarcinoma, although adenocarcinoma is also seen. Cervical cancer can beprevented by population screening as it evolves through well-definednoninvasive intraepithelial stages, which can be distinguishedmorphologically. Williams et al. (1998) Proc. Natl. Acad. Sci. USA95:14932-14937. While it is not understood how normal cells becometransformed, the concept of a continuous spectrum of histopathologicalchange from normal, stratified epithelium through cervicalintraepithelial neoplasia (CIN) to invasive cancer has been widelyaccepted for years. The precursor to cervical cancer is dysplasia, alsoknown in the art as CIN or squamous intraepithelial lesions (SIL).Squamous intraepithelial abnormalities may be classified by using thethree-tiered (CIN) or two-tiered (Bethesda) system. Under the Bethesdasystem, low-grade squamous intraepithelial lesions (LSIL), correspondingto CINI and HPV infection, generally represent productive HPV infectionswith a relatively low risk of progression to invasive disease.High-grade squamous intraepithelial lesions (HSIL), corresponding toCINII and CINIII in the three-tiered system, show a higher risk ofprogression to cervical cancer than do LSIL, although both LSIL and HSILare viewed as potential precursors of malignancy. Patient samples mayalso be classified as ASCUS (atypical squamous cells of unknownsignificance) or AGUS (atypical glandular cells of unknown significance)under this system.

A strong association of cervical cancer and infection by high-risk typesof human papilloma virus (HPV), such as types 16, 18, and 31, has beenestablished. In fact, a large body of epidemiological and molecularbiological evidence has established HPV infection as a causative factorin cervical cancer. Moreover, HPV is found in 85% or more of the casesof high-grade cervical disease. However, HPV infection is very common,possibly occurring in 5-15% of women over the age of 30, but fewHPV-positive women will ever develop high-grade cervical disease orcancer. The presence of HPV alone is indicative only of infection, notof high-grade cervical disease, and, therefore, testing for HPVinfection alone results in many false positives. See, for example,Wright et al. (2004) Obstet. Gynecol. 103:304-309.

Current literature suggests that HPV infects the basal stem cells withinthe underlying tissue of the uterine-cervix. Differentiation of the stemcells into mature keratinocytes, with resulting migration of the cellsto the stratified cervical epithelium, is associated with HPV viralreplication and re-infection of cells. During this viral replicationprocess, a number of cellular changes occur that include cell-cyclede-regulation, active proliferation, DNA replication, transcriptionalactivation and genomic instability (Crum (2000) Modern Pathology13:243-251; Middleton et al. (2003) J. Virol. 77:10186-10201; Pett etal. (2004) Cancer Res. 64:1359-1368).

Most HPV infections are transient in nature, with the viral infectionresolving itself within a 12-month period. For those individuals whodevelop persistent infections with one or more oncogenic subtypes ofHPV, there is a risk for the development of neoplasia in comparison topatients without an HPV infection. Given the importance of HPV in thedevelopment of cervical neoplasia, the clinical detection of HPV hasbecome an important diagnostic tool in the identification of patients atrisk for cervical neoplasia development. The clinical utility ofHPV-based screening for cervical disease is in its negative predictivevalue. An HPV negative result in combination with a history of normalPap smears is an excellent indicator of a disease-free condition and alow risk of cervical neoplasia development during the subsequent 1-3years. However, a positive HPV result is not diagnostic of cervicaldisease; rather it is an indication of infection. Although the majorityof HPV infections is transient and will spontaneously clear within a12-month period, a persistent infection with a high-risk HPV viralsubtype indicates a higher risk for the development of cervicalneoplasia. To supplement HPV testing, the identification of molecularmarkers associated with cervical neoplasia is expected to improve theclinical specificity for cervical disease diagnosis.

Cytological examination of Papanicolaou-stained cervical smears (Papsmears) currently is the method of choice for detecting cervical cancer.The Pap test is a subjective method that has remained substantiallyunchanged for 60 years. There are several concerns, however, regardingits performance. The reported sensitivity of a single Pap test (theproportion of disease positives that are test-positive) is low and showswide variation (30-87%). The specificity of a single Pap test (theproportion of disease negatives that are test-negative) might be as lowas 86% in a screening population and considerably lower in the ASCUSPLUS population for the determination of underlying high-grade disease.See, Baldwin et al., supra. A significant percentage of Pap smearscharacterized as LSIL or CINI are actually positive for high-gradelesions. Furthermore, up to 10% of Pap smears are classified as ASCUS(atypical squamous cells of undetermined significance), i.e., it is notpossible to make a clear categorization as normal, moderate or severelesion, or tumor. However, experience shows that up to 10% of this ASCUSpopulation has high-grade lesions, which are consequently overlooked.See, for example, Manos et al. (1999) JAMA 281:1605-1610. Therefore,molecular biomarkers that are selectively overexpressed in high-gradecervical disease and compositions for the detection of these biomarkersare needed to practice reliable methods for diagnosing high-gradecervical disease.

Minichromosome maintenance (MCM) proteins play an essential part ineukaryotic DNA replication. The minichromosome maintenance (MCM)proteins function in the early stages of DNA replication through loadingof the prereplication complex onto DNA and functioning as a helicase tohelp unwind the duplex DNA during de novo synthesis of the duplicate DNAstrand. Each of the MCM proteins has DNA-dependent ATPase motifs intheir highly conserved central domain. Levels of MCM proteins generallyincrease in a variable manner as normal cells progress from G0 into theG1/S phase of the cell cycle. In the G0 phase, MCM2 and MCM5 proteinsare much less abundant than are the MCM7 and MCM3 proteins. MCM6 forms acomplex with MCM2, MCM4, and MCM7, which binds histone H3. In addition,the subcomplex of MCM4, MCM6, and MCM7 has helicase activity, which ismediated by the ATP-binding activity of MCM6 and the DNA-bindingactivity of MCM4. See, for example, Freeman et al. (1999) Clin. CancerRes. 5:2121-2132; Lei et al. (2001) J. Cell Sci. 114:1447-1454; Ishimiet al. (2003) Eur. J. Biochem. 270:1089-1101, all of which are hereinincorporated by reference in their entirety.

Early publications have shown that the MCM proteins, and in particular,MCM5, are useful for the detection of cervical disease (Williams et al.(1998) Proc Natl Acad Sci U.S.A. 95:14932-14937), as well as othercancers (Freeman et al. (1999) Clin Cancer Res. 5:2121-2132). Thepublished literature indicates that antibodies to MCM5 are capable ofdetecting cervical neoplastic cells. The specificity for detection ofhigh-grade cervical disease has not been demonstrated for MCM5 (Williamset al. (1998) Proc Natl Acad Sci U.S.A. 95:14932-14937). The detectionof MCM5 expression is not restricted to high-grade cervical disease butis also detected in identified low-grade dysplasia and proliferativecells that have re-entered the cell cycle following infection withhigh-risk HPV. The detection of cervical neoplasia with antibodies toMCM5 is shown in FIG. 4. In addition to MCM5, other members from the MCMfamily, including MCM2 and MCM7 have been shown to be potentially usefulmarkers for the detection of cervical neoplasia in tissue samples(Freeman et al. (1999) Clin Cancer Res. 5:2121-2132; Brake et al. (2003)Cancer Res. 63:8173-8180). Recent results have shown that MCM7 appearsto be a specific marker for the detection of high-grade cervical diseaseusing immunochemistry formats (Brake et al. (2003) Cancer Res.63:8173-8180; Malinowski et al. (2004) Acta Cytol. 43:696).

Therefore, there is a need in the art for antibodies that are capable ofdetecting expression of a biomarker that is selectively overexpressed inhigh-grade cervical disease. Such antibodies could be used in methodsfor differentiating high-grade disease from conditions that are notconsidered clinical disease, such as early-stage HPV infection and milddysplasia.

SUMMARY OF THE INVENTION

Compositions and methods for diagnosing high-grade cervical disease areprovided. Compositions include monoclonal antibodies capable of bindingto nuclear biomarker proteins of the invention, particularly MCMproteins, more particularly MCM6 and MCM7. Antigen-binding fragments andvariants of these monoclonal antibodies, hybridoma cell lines capable ofproducing these antibodies, and kits comprising the monoclonalantibodies of the invention are also encompassed herein.

The compositions of the invention find use in methods for diagnosinghigh-grade cervical disease. The methods comprise detecting expressionof at least one nuclear biomarker, wherein overexpression of the nuclearbiomarker is indicative of high-grade cervical disease. Specifically,the methods comprise using the antibodies of the invention to detectoverexpression of MCM6 or MCM7 in a cervical sample.

Compositions of the invention further include isolated polypeptides thatcomprise an epitope capable of binding an MCM6 or MCM7 monoclonalantibody. These polypeptides find use in methods for producing MCM6 orMCM7 antibodies. Isolated nucleic acid molecules encoding the amino acidsequences of the MCM6 or MCM7 epitopes are also provided.

DETAILED DESCRIPTION OF THE INVENTION

Compositions and methods for diagnosing high-grade cervical disease areprovided. Compositions include monoclonal antibodies that are capable ofbinding to nuclear biomarker proteins that are selectively overexpressedin high-grade cervical disease, particularly MCM proteins, moreparticularly MCM6 and MCM7. Hybridoma cell lines that produce themonoclonal antibodies of the present invention are also disclosed. Kitscomprising the monoclonal antibodies described herein are furtherprovided. The present compositions find use in methods for diagnosinghigh-grade cervical disease in a patient.

The compositions of the invention include monoclonal antibodies thatspecifically bind to MCM6 or MCM7, or to a variant or fragment thereof.The amino acid and nucleotide sequences for MCM6 are set forth in SEQ IDNO:3 (Accession No. NP_(—)005906) and SEQ ID NO:4 (Accession No.NM_(—)005915), respectively. The amino acid and nucleotide sequences forMCM7 are set forth in SEQ ID NO:1 (Accession No. NP_(—)005907) and SEQID NO:2 (Accession No. NM_(—)005916), respectively. In particularembodiments, the MCM6 monoclonal antibody designated as 9D4.3 and theMCM7 monoclonal antibody designated as 2E6.2 are provided. A hybridomacell line that produces MCM7 monoclonal antibody 2E6.2 was depositedwith the Patent Depository of the American Type Culture Collection(ATCC), Manassas, Va., 20110-2209 on Apr. 14, 2005 and assigned PatentDeposit No. PTA-6669. A hybridoma cell line that produces MCM6monoclonal antibody 9D4.3 was deposited with the Patent Depository ofthe American Type Culture Collection (ATCC), Manassas, Va., 20110-2209on Aug. 9, 2005 and assigned Patent Deposit No. PTA-6911. These depositswill be maintained under the terms of the Budapest Treaty on theInternational Recognition of the Deposit of Microorganisms for thePurposes of Patent Procedure. This deposit was made merely as aconvenience for those of skill in the art and are not an admission thata deposit is required under 35 U.S.C. § 112.

Antibodies that have the binding characteristics of monoclonal antibody9D4.3 and 2E6.2 are also disclosed herein. Such antibodies include, butare not limited to, antibodies that compete in competitive bindingassays with these antibodies, as well as antibodies that bind to anepitope capable of binding monoclonal antibody 9D4.3 or 2E6.2. Variantsand fragments of monoclonal antibody 9D4.3 and 2E6.2 that retain theability to specifically bind to MCM6 or MCM7, respectively, are alsoprovided. Compositions further include hybridoma cell lines that producethe monoclonal antibodies of the present invention and kits comprisingat least one monoclonal antibody disclosed herein.

“Antibodies” and “immunoglobulins” (Igs) are glycoproteins having thesame structural characteristics. While antibodies exhibit bindingspecificity to an antigen, immunoglobulins include both antibodies andother antibody-like molecules that lack antigen specificity.Polypeptides of the latter kind are, for example, produced at low levelsby the lymph system and at increased levels by myelomas.

The terms “antibody” and “antibodies” broadly encompass naturallyoccurring forms of antibodies and recombinant antibodies such assingle-chain antibodies, chimeric and humanized antibodies andmulti-specific antibodies as well as fragments and derivatives of all ofthe foregoing, which fragments and derivatives have at least anantigenic binding site. Antibody derivatives may comprise a protein orchemical moiety conjugated to the antibody. The term “antibody” is usedin the broadest sense and covers fully assembled antibodies, antibodyfragments that can bind antigen (e.g., Fab′, F′(ab)₂, Fv, single chainantibodies, diabodies), and recombinant peptides comprising theforegoing. As used herein, “MCM6 antibody” or “MCM7 antibody” refers toany antibody that specifically binds to MCM6 (SEQ ID NO:3) or MCM7 (SEQID NO:1), or to a variant or fragment thereof, and includes monoclonalantibodies, polyclonal antibodies, single-chain antibodies, andfragments thereof which retain the antigen binding function of theparent antibody.

The MCM6 and MCM7 antibodies of the invention are optimally monoclonalantibodies. The term “monoclonal antibody” as used herein refers to anantibody obtained from a population of substantially homogeneousantibodies, i.e., the individual antibodies comprising the populationare identical except for possible naturally-occurring mutations that maybe present in minor amounts.

“Native antibodies” and “native immunoglobulins” are usuallyheterotetrameric glycoproteins of about 150,000 daltons, composed of twoidentical light (L) chains and two identical heavy (H) chains. Eachlight chain is linked to a heavy chain by one covalent disulfide bond,while the number of disulfide linkages varies among the heavy chains ofdifferent immunoglobulin isotypes. Each heavy and light chain also hasregularly spaced intrachain disulfide bridges. Each heavy chain has atone end a variable domain (VH) followed by a number of constant domains.Each light chain has a variable domain at one end (V,) and a constantdomain at its other end; the constant domain of the light chain isaligned with the first constant domain of the heavy chain, and the lightchain variable domain is aligned with the variable domain of the heavychain. Particular amino acid residues are believed to form an interfacebetween the light and heavy-chain variable domains.

The term “variable” refers to the fact that certain portions of thevariable domains differ extensively in sequence among antibodies and areused in the binding and specificity of each particular antibody for itsparticular antigen. However, the variability is not evenly distributedthroughout the variable domains of antibodies. It is concentrated inthree segments called complementarity determining regions (CDRs) orhypervariable regions both in the light chain and the heavy-chainvariable domains. The more highly conserved portions of variable domainsare called the framework (FR) regions. The variable domains of nativeheavy and light chains each comprise four FR regions, largely adopting ap-sheet configuration, connected by three CDRs, which form loopsconnecting, and 15 in some cases forming part of, the p-sheet structure.The CDRs in each chain are held together in close proximity: by the FRregions and, with the CDRs from the other chain, contribute to theformation of the antigen-binding site: of antibodies (see Kabat et al.,NIH Publ. No. 91-3242, Vol. I, pages 647-669 (1991)).

The constant domains are not involved directly in binding an antibody toan antigen, but exhibit various effecter functions, such asparticipation of the antibody in antibody-dependent cellular toxicity.

The term “hypervariable region” when used herein refers to the aminoacid residues of an antibody which: are responsible for antigen-binding.The hypervariable region comprises amino acid residues from a“complementarily determining region” or “CDR” (i.e., residues 24-34(L1), 50-56 (L2) and 89-97 (L3) in the light chain variable domain and31-35 (H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variabledomain; Kabat et al., Sequences of Proteins of Immunological Interest,5th Ed. Public Health Service, National Institute of Health, 25Bethesda, Md. [1991]) and/or those residues from a “hypervariable loop”(i.e., residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light chainvariable domain and 2632 (H1), 53-55 (H2) and 96-101 (H3) in the heavychain variable domain; Clothia and Lesk, J. Mol. Biol., 196:901-917[1987]). Framework” or “FR” residues are those variable domain residuesother than the hypervariable region residues as herein deemed.

“Antibody fragments” comprise a portion of an intact antibody,preferably the antigen-binding or variable region of the intactantibody. Examples of antibody fragments include Fab, Fab′, F(ab′)2, andFv fragments; diabodies; linear antibodies (Zapata et al. (1995) ProteinEng. 8(10):1057-1062); single-chain antibody molecules; andmultispecific antibodies formed from antibody fragments. Papaindigestion of antibodies produces two identical antigen-bindingfragments, called “Fab” fragments, each with a single antigen-bindingsite, and a residual “Fc” fragment, whose name reflects its ability tocrystallize readily. Pepsin treatment yields an F(ab′)2 fragment thathas two antigen-combining sites and is still capable of cross-linkingantigen.

“Fv” is the minimum antibody fragment that contains a complete antigenrecognition and binding site. In a two-chain Fv species, this regionconsists of a dimer of one heavy- and one light-chain variable domain intight, non-covalent association. In a single-chain Fv species, oneheavy- and one light-chain variable domain can be covalently linked byflexible peptide linker such that the light and heavy chains canassociate in a “dimeric” structure analogous to that in a two-chain Fvspecies. It is in this configuration that the three CDRs of eachvariable domain interact to define an antigen-binding site on thesurface of the V_(H)-V_(L) dimer. Collectively, the six CDRs conferantigen-binding specificity to the antibody. However, even a singlevariable domain (or half of an Fv comprising only three CDRs specificfor an antigen) has the ability to recognize and bind antigen, althoughat a lower affinity than the entire binding site.

The Fab fragment also contains the constant domain of the light chainand the first constant domain (C_(H)1) of the heavy chain. Fab fragmentsdiffer from Fab′ fragments by the addition of a few residues at thecarboxy terminus of the heavy-chain C_(H)1 domain including one or morecysteines from the antibody hinge region. Fab′-SH is the designationherein for Fab′ in which the cysteine residue(s) of the constant domainsbear a free thiol group. F(ab′)2 antibody fragments originally wereproduced as pairs of Fab′ fragments that have hinge cysteines betweenthem.

Fragments of the MCM6 and MCM7 antibodies are encompassed by theinvention so long as they retain the desired affinity of the full-lengthantibody. Thus, for example, a fragment of an MCM6 antibody will retainthe ability to bind to an MCM6 antigen. Similarly, a fragment of an MCM7antibody will retain the ability to bind to an MCM7 antigen. Suchfragments are characterized by properties similar to the correspondingfull-length antibody, that is, the fragments will specifically bind MCM6or MCM7. Such fragments are referred to herein as “antigen-binding”fragments.

Suitable antigen-binding fragments of an antibody comprise a portion ofa full-length antibody, generally the antigen-binding or variable regionthereof. Examples of antibody fragments include, but are not limited to,Fab, F(ab′)₂, and Fv fragments and single-chain antibody molecules. By“Fab” is intended a monovalent antigen-binding fragment of animmunoglobulin that is composed of the light chain and part of the heavychain. By F(ab′)₂ is intended a bivalent antigen-binding fragment of animmunoglobulin that contains both light chains and part of both heavychains. By “single-chain Fv” or “sFv” antibody fragments is intendedfragments comprising the V_(H) and V_(L) domains of an antibody, whereinthese domains are present in a single polypeptide chain. See, forexample, U.S. Pat. Nos. 4,946,778, 5,260,203, 5,455,030, and 5,856,456,herein incorporated by reference. Generally, the Fv polypeptide furthercomprises a polypeptide linker between the V_(H) and V_(L) domains thatenables the sFv to form the desired structure for antigen binding. For areview of sFv see Pluckthun (1994) in The Pharmacology of MonoclonalAntibodies, Vol. 113, ed. Rosenburg and Moore (Springer-Verlag, NewYork), pp. 269-315.

Antibodies or antibody fragments can be isolated from antibody phagelibraries generated using the techniques described in, for example,McCafferty et al. (1990) Nature 348:552-554 (1990) and U.S. Pat. No.5,514,548. Clackson et al. (1991) Nature 352:624-628 and Marks et al.(1991) J. Mol. Biol. 222:581-597 describe the isolation of murine andhuman antibodies, respectively, using phage libraries. Subsequentpublications describe the production of high affinity (nM range) humanantibodies by chain shuffling (Marks et al. (1992) Bio/Technology10:779-783), as well as combinatorial infection and in vivorecombination as a strategy for constructing very large phage libraries(Waterhouse et al. (1993) Nucleic. Acids Res. 21:2265-2266). Thus, thesetechniques are viable alternatives to traditional monoclonal antibodyhybridoma techniques for isolation of monoclonal antibodies.

Various techniques have been developed for the production of antibodyfragments. Traditionally, these fragments were derived via proteolyticdigestion of intact antibodies (see, e.g., Morimoto et al. (1992)Journal of Biochemical and Biophysical Methods 24:107-117 (1992) andBrennan et al. (1985) Science 229:81). However, these fragments can nowbe produced directly by recombinant host cells. For example, theantibody fragments can be isolated from the antibody phage librariesdiscussed above. Alternatively, Fab′-SH fragments can be directlyrecovered from E. coli and chemically coupled to form F(ab′)₂ fragments(Carter et al. (1992) Bio/Technology 10:163-167). According to anotherapproach, F(ab′)₂ fragments can be isolated directly from recombinanthost cell culture. Other techniques for the production of antibodyfragments will be apparent to the skilled practitioner.

Preferably antibodies of the invention are monoclonal in nature. Asindicated above, “monoclonal antibody” is intended an antibody obtainedfrom a population of substantially homogeneous antibodies, i.e., theindividual antibodies comprising the population are identical except forpossible naturally occurring mutations that may be present in minoramounts. The term is not limited regarding the species or source of theantibody. The term encompasses whole immunoglobulins as well asfragments such as Fab, F(ab′)2, Fv, and others which retain the antigenbinding function of the antibody. Monoclonal antibodies are highlyspecific, being directed against a single antigenic site, i.e., aparticular epitope within the MCM6 or MCM7 protein, as defined hereinbelow. Furthermore, in contrast to conventional (polyclonal) antibodypreparations that typically include different antibodies directedagainst different determinants (epitopes), each monoclonal antibody isdirected against a single determinant on the antigen. The modifier“monoclonal” indicates the character of the antibody as being obtainedfrom a substantially homogeneous population of antibodies, and is not tobe construed as requiring production of the antibody by any particularmethod. For example, the monoclonal antibodies to be used in accordancewith the present invention may be made by the hybridoma method firstdescribed by Kohler et al. (1975) Nature 256:495, or may be made byrecombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567). The“monoclonal antibodies” may also be isolated from phage antibodylibraries using the techniques described in, for example, Clackson etal. (1991) Nature 352:624-628; Marks et al. (1991) J. Mol. Biol.222:581-597; and U.S. Pat. No. 5,514,548.

Monoclonal antibodies can be prepared using the method of Kohler et al.(1975) Nature 256:495-496, or a modification thereof. Typically, a mouseis immunized with a solution containing an antigen. Immunization can beperformed by mixing or emulsifying the antigen-containing solution insaline, preferably in an adjuvant such as Freund's complete adjuvant,and injecting the mixture or emulsion parenterally. Any method ofimmunization known in the art may be used to obtain the monoclonalantibodies of the invention. After immunization of the animal, thespleen (and optionally, several large lymph nodes) are removed anddissociated into single cells. The spleen cells may be screened byapplying a cell suspension to a plate or well coated with the antigen ofinterest. The B cells expressing membrane bound immunoglobulin specificfor the antigen (i.e., antibody-producing cells) bind to the plate andare not rinsed away. Resulting B cells, or all dissociated spleen cells,are then induced to fuse with myeloma cells to form monoclonalantibody-producing hybridomas, and are cultured in a selective medium.The resulting cells are plated by serial dilution and are assayed forthe production of antibodies that specifically bind the antigen ofinterest (and that do not bind to unrelated antigens). The selectedmonoclonal antibody (mAb)-secreting hybridomas are then cultured eitherin vitro (e.g., in tissue culture bottles or hollow fiber reactors), orin vivo (as ascites in mice). Monoclonal antibodies can also be producedusing Repetitive Immunizations Multiple Sites technology (RIMMS). See,for example, Kilpatrick et al. (1997) Hybridoma 16(4):381-389; Wring etal. (1999) J. Pharm. Biomed. Anal. 19(5):695-707; and Bynum et al.(1999) Hybridoma 18(5):407-411, all of which are herein incorporated byreference in their entirety.

As an alternative to the use of hybridomas, antibody can be produced ina cell line such as a CHO cell line, as disclosed in U.S. Pat. Nos.5,545,403; 5,545,405; and 5,998,144; incorporated herein by reference.Briefly the cell line is transfected with vectors capable of expressinga light chain and a heavy chain, respectively. By transfecting the twoproteins on separate vectors, chimeric antibodies can be produced.Another advantage is the correct glycosylation of the antibody. Amonoclonal antibody can also be identified and isolated by screening arecombinant combinatorial immunoglobulin library (e.g., an antibodyphage display library) with a biomarker protein to thereby isolateimmunoglobulin library members that bind the biomarker protein. Kits forgenerating and screening phage display libraries are commerciallyavailable (e.g., the Pharmacia Recombinant Phage Antibody System,Catalog No. 27-9400-01; and the Stratagene SurfZAP

Phage Display Kit, Catalog No. 240612). Additionally, examples ofmethods and reagents particularly amenable for use in generating andscreening antibody display library can be found in, for example, U.S.Pat. No. 5,223,409; PCT Publication Nos. WO 92/18619; WO 91/17271; WO92/20791; WO 92/15679; 93/01288; WO 92/01047; 92/09690; and 90/02809;Fuchs et al. (1991) Bio/Technology 9:1370-1372; Hay et al. (1992) Hum.Antibod. Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281;Griffiths et al. (1993) EMBO J. 12:725-734.

In some aspects of the invention, antibodies may be selected on thebasis of desirable staining of cytological, rather than histological,samples. That is, in particular embodiments the antibodies are selectedwith the end sample type (e.g., cytology preparations) in mind and forbinding specificity. Antibodies directed to specific biomarkers ofinterest, such as MCM6 or MCM7, are selected and purified via amulti-step screening process. Such methods for antibody selection aredescribed in pending U.S. application Ser. No. 11/087,227, entitled“Methods and Compositions for the Detection of Cervical Disease,” filedMar. 23, 2005, which is herein incorporated by reference in itsentirety.

Antibodies having the binding characteristics of a monoclonal antibodyof the invention are also provided. “Binding characteristics” or“binding specificity” when used in reference to an antibody means thatthe antibody recognizes the same or similar antigenic epitope as acomparison antibody. Examples of such antibodies include, for example,an antibody that competes with a monoclonal antibody of the invention ina competitive binding assay. One of skill in the art could determinewhether an antibody competitively interferes with another antibody usingstandard methods.

By “epitope” is intended the part of an antigenic molecule to which anantibody is produced and to which the antibody will bind. An “MCM6epitope” comprises the part of the MCM6 protein to which an MCM6monoclonal antibody binds. An “MCM7 epitope” comprises the part of theMCM7 protein to which an MCM7 monoclonal antibody binds. Epitopes cancomprise linear amino acid residues (i.e., residues within the epitopeare arranged sequentially one after another in a linear fashion),nonlinear amino acid residues (referred to herein as “nonlinearepitopes”; these epitopes are not arranged sequentially), or both linearand nonlinear amino acid residues. Typically epitopes are short aminoacid sequences, e.g. about five amino acids in length. Systematictechniques for identifying epitopes are known in the art and aredescribed, for example, in U.S. Pat. No. 4,708,871 and in the examplesset forth below. Briefly, in one method, a set of overlappingoligopeptides derived from the antigen may be synthesized and bound to asolid phase array of pins, with a unique oligopeptide on each pin. Thearray of pins may comprise a 96-well microtiter plate, permitting one toassay all 96 oligopeptides simultaneously, e.g., for binding to abiomarker-specific monoclonal antibody. Alternatively, phage displaypeptide library kits (New England BioLabs) are currently commerciallyavailable for epitope mapping. Using these methods, the binding affinityfor every possible subset of consecutive amino acids may be determinedin order to identify the epitope that a given antibody binds. Epitopesmay also be identified by inference when epitope length peptidesequences are used to immunize animals from which antibodies areobtained.

The invention also encompasses isolated polypeptides comprising anepitope for binding an MCM6 or MCM7 monoclonal antibody. Thesepolypeptides correspond to a portion of the antigen (i.e., MCM6 or MCM7)that binds to a monoclonal antibody. Such polypeptides find use inmethods for producing antibodies that bind selectively to MCM6 or MCM7.The ability of a polypeptide to be used in the production of antibodiesis referred to herein as “antigenic activity.” For example, the aminoacid sequence set forth in SEQ ID NO:5 (corresponding to residues760-772 in the MCM6 amino acid sequence set forth in SEQ ID NO:3)comprise an epitope recognized by an MCM6 monoclonal antibody, moreparticularly monoclonal antibody 9D4.3. The amino acid sequence setforth in SEQ ID NO:6 (corresponding to residues 127-138 in the MCM7amino acid sequence set forth in SEQ ID NO:1) comprise an epitoperecognized by an MCM7 monoclonal antibody, more particularly monoclonalantibody 2E6.2. Variants and fragments of the MCM6 and MCM7 epitopesequences set forth in SEQ ID NOs:5 and 6 that retain the antigenicactivity of the original polypeptide are also provided. The inventionfurther includes isolated nucleic acid molecules that encodepolypeptides that comprise MCM6 or MCM7 epitopes, and variants andfragments thereof.

The polypeptides of the invention comprising MCM6 or MCM7 epitopes canbe used in methods for producing monoclonal antibodies that specificallybind to MCM6 or MCM7, as described herein above. Such polypeptides canalso be used in the production of polyclonal MCM6 or MCM7 antibodies.For example, polyclonal antibodies can be prepared by immunizing asuitable subject (e.g., rabbit, goat, mouse, or other mammal) with apolypeptide comprising an MCM6 or MCM7 epitope (i.e., an immunogen). Theantibody titer in the immunized subject can be monitored over time bystandard techniques, such as with an enzyme linked immunosorbent assay(ELISA) using immobilized biomarker protein. At an appropriate timeafter immunization, e.g., when the antibody titers are highest,antibody-producing cells can be obtained from the subject and used toprepare monoclonal antibodies by standard techniques, such as thehybridoma technique originally described by Kohler and Milstein (1975)Nature 256:495-497, the human B cell hybridoma technique (Kozbor et al.(1983) Immunol. Today 4:72), the EBV-hybridoma technique (Cole et al.(1985) in Monoclonal Antibodies and Cancer Therapy, ed. Reisfeld andSell (Alan R. Liss, Inc., New York, N.Y.), pp. 77-96) or triomatechniques. The technology for producing hybridomas is well known (seegenerally Coligan et al., eds. (1994) Current Protocols in Immunology(John Wiley & Sons, Inc., New York, N.Y.); Galfre et al. (1977) Nature266:550-52; Kenneth (1980) in Monoclonal Antibodies: A New Dimension InBiological Analyses (Plenum Publishing Corp., NY; and Lerner (1981) YaleJ. Biol. Med., 54:387-402).

Amino acid sequence variants of a monoclonal antibody or a polypeptidecomprising an MCM6 or MCM7 epitope described herein are also encompassedby the present invention. Variants can be prepared by mutations in thecloned DNA sequence encoding the antibody of interest. Methods formutagenesis and nucleotide sequence alterations are well known in theart. See, for example, Walker and Gaastra, eds. (1983) Techniques inMolecular Biology (MacMillan Publishing Company, New York); Kunkel(1985) Proc. Natl. Acad. Sci. USA 82:488-492; Kunkel et al. (1987)Methods Enzymol. 154:367-382; Sambrook et al. (1989) Molecular Cloning:A Laboratory Manual (Cold Spring Harbor, N.Y.); U.S. Pat. No. 4,873,192;and the references cited therein; herein incorporated by reference.Guidance as to appropriate amino acid substitutions that do not affectbiological activity of the polypeptide of interest may be found in themodel of Dayhoff et al. (1978) in Atlas of Protein Sequence andStructure (Natl. Biomed. Res. Found., Washington, D.C.), hereinincorporated by reference. Conservative substitutions, such asexchanging one amino acid with another having similar properties, may bepreferred. Examples of conservative substitutions include, but are notlimited to, Gly

Ala, Val

Ile

Leu, Asp

Glu, Lys

Arg, Asn

Gln, and Phe

Trp

Tyr.

In constructing variants of the polypeptide of interest, modificationsare made such that variants continue to possess the desired activity,i.e., similar binding affinity to the biomarker. Obviously, anymutations made in the DNA encoding the variant polypeptide must notplace the sequence out of reading frame and preferably will not createcomplementary regions that could produce secondary mRNA structure. SeeEP Patent Application Publication No. 75,444.

Preferably, variants of a reference polypeptide have amino acidsequences that have at least 70% or 75% sequence identity, preferably atleast 80% or 85% sequence identity, more preferably at least 90%, 91%,92%, 93%, 94% or 95% sequence identity to the amino acid sequence forthe reference antibody molecule, or to a shorter portion of thereference antibody molecule. More preferably, the molecules share atleast 96%, 97%, 98% or 99% sequence identity. For purposes of thepresent invention, percent sequence identity is determined using theSmith-Waterman homology search algorithm using an affine gap search witha gap open penalty of 12 and a gap extension penalty of 2, BLOSUM matrixof 62. The Smith-Waterman homology search algorithm is taught in Smithand Waterman (1981) Adv. Appl. Math. 2:482-489. A variant may, forexample, differ from the reference antibody by as few as 1 to 15 aminoacid residues, as few as 1 to 10 amino acid residues, such as 6-10, asfew as 5, as few as 4, 3, 2, or even 1 amino acid residue.

With respect to optimal alignment of two amino acid sequences, thecontiguous segment of the variant amino acid sequence may haveadditional amino acid residues or deleted amino acid residues withrespect to the reference amino acid sequence. The contiguous segmentused for comparison to the reference amino acid sequence will include atleast 20 contiguous amino acid residues, and may be 30, 40, 50, or moreamino acid residues. Corrections for sequence identity associated withconservative residue substitutions or gaps can be made (seeSmith-Waterman homology search algorithm).

The MCM6 and MCM7 monoclonal antibodies of the invention may be labeledwith a detectable substance as described below to facilitate biomarkerprotein detection in the sample. Such antibodies find use in practicingthe methods of the invention. The antibodies and antibody fragments ofthe invention can be coupled to a detectable substance to facilitatedetection of antibody binding. The word “label” when used herein refersto a detectable compound or composition that is conjugated directly orindirectly to the antibody so as to generate a “labeled” antibody. Thelabel may be detectable by itself (e.g., radioisotope labels orfluorescent labels) or, in the case of an enzymatic label, may catalyzechemical alteration of a substrate compound or composition that isdetectable. Examples of detectable substances for purposes of labelingantibodies include various enzymes, prosthetic groups, fluorescentmaterials, luminescent materials, bioluminescent materials, andradioactive materials. Examples of suitable enzymes include horseradishperoxidase, alkaline phosphatase, β-galactosidase, oracetylcholinesterase; examples of suitable prosthetic group complexesinclude streptavidin/biotin and avidin/biotin; examples of suitablefluorescent materials include umbelliferone, fluorescein, fluoresceinisothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansylchloride or phycoerythrin; an example of a luminescent material includesluminol; examples of bioluminescent materials include luciferase,luciferin, and aequorin; and examples of suitable radioactive materialinclude ¹²⁵I, ¹³¹I, ³⁵S, or ³H.

Kits comprising at least one MCM6 or one MCM7 monoclonal antibody of theinvention are further provided. By “kit” is intended any manufacture(e.g., a package or a container) comprising at least one reagent, i.e.,an antibody, for specifically detecting the expression of MCM6 or MCM7.The kit may be promoted, distributed, or sold as a unit for performingthe methods of the present invention. Additionally, the kits may containa package insert describing the kit and methods for its use.

Kits of the invention generally comprise at least one monoclonalantibody directed to MCM6 or MCM7, chemicals for the detection ofantibody binding, a counterstain, and, optionally, a bluing agent tofacilitate identification of positive staining cells. Any chemicals thatdetect antigen-antibody binding may be used in the kits of theinvention. In some embodiments, the detection chemicals comprise alabeled polymer conjugated to a secondary antibody. For example, asecondary antibody that is conjugated to an enzyme that catalyzes thedeposition of a chromogen at the antigen-antibody binding site may beprovided. Such enzymes and techniques for using them in the detection ofantibody binding are well known in the art. In one embodiment, the kitcomprises a secondary antibody that is conjugated to an HRP-labeledpolymer. Chromogens compatible with the conjugated enzyme (e.g., DAB inthe case of an HRP-labeled secondary antibody) and solutions, such ashydrogen peroxide, for blocking non-specific staining may be furtherprovided. In other embodiments, antibody binding to a biomarker proteinis detected through the use of a mouse probe reagent that binds tomonoclonal antibodies, followed by addition of a dextran polymerconjugated with HRP that binds to the mouse probe reagent. Suchdetection reagents are commercially available from, for example, BiocareMedical.

The kits of the present invention may further comprise a peroxidaseblocking reagent (e.g., hydrogen peroxide), a protein blocking reagent(e.g., purified casein), and a counterstain (e.g., hematoxylin). Abluing agent (e.g., ammonium hydroxide or TBS, pH 7.4, with Tween-20 andsodium azide) may be further provided in the kit to facilitate detectionof positive staining cells. Kits may also comprise positive and negativecontrol samples for quality control purposes.

In another embodiment, the kits of the invention comprise at least twomonoclonal antibodies. In certain aspects of the invention, the kitscomprise an MCM6 and an MCM7 antibody, more particularly the MCM6monoclonal antibody 9D4.3 and the MCM7 antibody 2E6.2. When multipleantibodies are present in the kit, each antibody may be provided as anindividual reagent or, alternatively, as an antibody cocktail comprisingall of the antibodies of interest. Furthermore, any or all of the kitreagents may be provided within containers that protect them from theexternal environment, such as in sealed containers. The kits of theinvention are useful in the diagnosis of high-grade cervical disease andmay further include reagents for Pap staining (e.g., EA50 and Orange G).

The compositions of the invention find use in methods for diagnosinghigh-grade cervical disease in a patient such as those disclosed inpending U.S. application Ser. No. 11/087,227, entitled “Methods andCompositions for the Detection of Cervical Disease,” filed Mar. 23,2005, which is herein incorporated by reference in its entirety.“Diagnosing high-grade cervical disease” is intended to include, forexample, diagnosing or detecting the presence of cervical disease,monitoring the progression of the disease, and identifying or detectingcells or samples that are indicative of high-grade cervical disease. Theterms diagnosing, detecting, and identifying high-grade cervical diseaseare used interchangeably herein. By “high-grade cervical disease” isintended those conditions classified by colposcopy as premalignantpathology, malignant pathology, moderate to severe dysplasia, andcervical cancer. Underlying high-grade cervical disease includeshistological identification of CINII, CINIII, HSIL, carcinoma in situ,adenocarcinoma, and cancer (FIGO stages I-IV).

The methods of the invention comprise detecting overexpression of atleast one nuclear biomarker that is selectively overexpressed inhigh-grade cervical disease. By “nuclear biomarker” is intended any geneof protein that is predominantly expressed in the nucleus of the cell. Anuclear biomarker may be expressed to a lesser degree in other parts ofthe cell. By “selectively overexpressed in high-grade cervical disease”is intended that the nuclear biomarker of interest is overexpressed inhigh-grade cervical disease but is not overexpressed in conditionsclassified as LSIL, CINI, HPV-infected samples without any dysplasiapresent, immature metaplastic cells, and other conditions that are notconsidered to be clinical disease. Thus, detection of the nuclearbiomarkers of the invention permits the differentiation of samplesindicative of underlying high-grade cervical disease from samples thatare indicative of benign proliferation, early-stage HPV infection, ormild dysplasia. Nuclear biomarkers of particular interest include MCMproteins, particularly MCM6 and MCM7.

In a particular aspect of the invention, the methods comprise obtaininga cervical sample from a patient, contacting the sample with at leastone MCM6 or MCM7 monoclonal antibody of the invention, and detectingbinding of the antibody to the MCM protein. In other embodiments, thesample is contacted with at least two monoclonal antibodies, a firstantibody that specifically binds to MCM6, particularly monoclonalantibody 9D4.3, and a second antibody that specifically binds to MCM7,particularly monoclonal antibody 2E6.2. Techniques for detectingantibody binding are well known in the art. Antibody binding to abiomarker of interest may be detected through the use of chemicalreagents that generate a detectable signal that corresponds to the levelof antibody binding and, accordingly, to the level of biomarker proteinexpression. Any method for detecting antibody-antigen binding may usedto practice the methods of the invention.

As used herein, “cervical sample” refers to any sampling of cells,tissues, or bodily fluids from the cervix in which expression of abiomarker can be detected. Examples of such body samples include but arenot limited to gynecological fluids, biopsies, and smears. Cervicalsamples may be obtained from a patient by a variety of techniquesincluding, for example, by scraping or swabbing an area or by using aneedle to aspirate bodily fluids. Methods for collecting cervicalsamples are well known in the art. In particular embodiments, thecervical sample comprises cervical cells, particularly in a liquid-basedpreparation. In one embodiment, cervical samples are collected accordingto liquid-based cytology specimen preparation guidelines such as, forexample, the SUREPATH® (TriPath Imaging, Inc.) or the THINPREP®preparation (CYTYC, Inc.). Cervical samples may be transferred to aglass slide for viewing under magnification. Fixative and stainingsolutions may be applied to the cells on the glass slide for preservingthe specimen and for facilitating examination. In one embodiment thecervical sample will be collected and processed to provide a monolayersample, as set forth in U.S. Pat. No. 5,346,831, herein incorporated byreference.

One of skill in the art will appreciate that any or all of the steps inthe methods of the invention could be implemented by personnel in amanual or automated fashion. Thus, the steps of cervical samplepreparation, antibody, and detection of antibody binding may beautomated. The methods of the invention may also be combined withconventional Pap staining techniques to permit a more accurate diagnosisof high-grade cervical disease.

The following examples are offered by way of illustration and not by wayof limitation:

EXPERIMENTAL Example 1 Production of Mouse Monoclonal Antibodies to MCM7

Mouse monoclonal antibodies specific for MCM7 were generated. Theantigen (an immunogenic polypeptide) was a recombinanthexahistidine-tagged N-terminal fragment of the MCM7 protein. Theantigen was expressed using a baculovirus expression system in Tnicells. Specifically, the coding sequence for the hexahistidine-taggedMCM7 N-terminal fragment (SEQ ID NO:7) was cloned into the pFastBac1plasmid (Invitrogen) for expression in Tni cells. Methods for producingrecombinant proteins using baculovirus expression systems are well knownin the art. The tagged MCM7 fragment was purified using a chelatingagarose charged with Ni+2 ions (Ni—NTA from Qiagen) and used as animmunogen. The amino acid sequence of the immunogenic MCM7 N-terminalpolypeptide fragment is provided in SEQ ID NO:8.

Mouse immunizations and hybridoma fusions were performed essentially asdescribed in Kohler et al. (1975) Nature 256:495-496. Mice wereimmunized with the immunogenic tagged-MCM7 fragment in solution.Antibody-producing cells were isolated from the immunized mice and fusedwith myeloma cells to form monoclonal antibody-producing hybridomas. Thehybridomas were cultured in a selective medium. The resulting cells wereplated by serial dilution and assayed for the production of antibodiesthat specifically bind MCM7 (and that do not bind to unrelatedantigens). To confirm that the monoclonal antibodies of interest reactedwith the MCM7 protein only and not with the hexahistidine tag, selectedhybridomas were screened against an MCM7-FLAG-tagged protein. Selectedmonoclonal antibody (mAb)-secreting hybridomas were then cultured.

Antibodies were purified from the culture media supernatants of“exhausted” hybridoma cells (i.e., cells grown until viability drops tobetween 0-15%) using recombinant Protein A-coated resin (STREAMLINE®,Amersham, Inc.). Antibodies were eluted using low pH followed byimmediate neutralization of pH. Fractions with significant absorbancesat 280 nM were pooled. The resultant pool was dialyzed against PBS.Purified antibodies were subjected to further characterization. MCM7monoclonal antibody 2E6.2 was determined to be an IgG₁ isotype. Detailsof the epitope mapping of this antibody are described below.

Example 2 Production of Mouse Monoclonal Antibodies to MCM6

Mouse monoclonal antibodies specific for MCM6 were generated. Theantigen (an immunogenic polypeptide) was a recombinant FLAG-tagged MCM6protein. The antigen was expressed using a proprietary expression vectorfrom Cell & Molecular Technology, Inc. in HEK293 cells or alternativelyexpressed using a baculovirus expression system in Tni cells. The codingsequence for the FLAG-tagged MCM6 is set forth in SEQ ID NO:9.FLAG-tagged MCM6 was purified from cell lysates using the anti-FLAG M2Affinity Gel matrix and the FLAG peptide for elution (Sigma ChemicalCo., St. Louis, Mo.). The FLAG-tagged MCM6 protein used as an immunogen.The amino acid sequence of the immunogenic FLAG-tagged MCM6 polypeptideis provided in SEQ ID NO:10.

Mouse immunizations and lymphocyte fusion were performed by RIMMStechnology, essentially as described in Kilpatrick et al. (1997)Hybridoma 16(4):381-389. Mice were immunized with the immunogenicFLAG-tagged-MCM6. Primary screening of uncloned hybridoma supernatantswas performed using recombinant MCM6 protein. Secondary screening andscreening of cloned hybridoma supernatants was performed using aseparate batch of recombinant MCM6 protein. Selected monoclonal antibody(mAb)-secreting hybridomas were then cultured.

Antibodies were purified from the culture media supernatants of“exhausted” hybridoma cells (i.e., cells grown until viability drops tobetween 0-15%) using recombinant Protein A-coated resin (STREAMLINE®,Amersham, Inc.). Antibodies were eluted using low pH followed byimmediate neutralization of pH. Fractions with significant absorbancesat 280 nM were pooled. The resultant pool was dialyzed against PBS.Purified antibodies were subjected to further characterization. MCM6monoclonal antibody 9D4.3 was determined to be an IgG_(2a) isotype.Details of the epitope mapping of this antibody are described below.

Example 3 Isolation of Monoclonal Antibodies from Hybridoma Cells

The following procedure is used to isolate monoclonal antibodies fromhybridoma cells:

Media Preparation

-   -   To a sterile 1,000 ml storage bottle, add 100 ml Hyclone Fetal        Bovine Serum (FBS).    -   Add 10 ml of MEM Non-Essential Amino Acids Solution.    -   Add 10 ml of Penicillin-Streptomycin-L-Glutamine Solution.    -   QS to approximately 1000 ml with ExCell 610-HSF media.    -   Place sterile cap on bottle and secure tightly. Swirl gently to        mix.    -   Connect a 1000 ml sterile acetate vacuum filter unit (0.2 μm) to        a vacuum pump system.    -   Gently pour approximately half of the media solution into        sterile acetate vacuum filter unit and turn on the vacuum.    -   Once the first half of the media has been filtered, pour the        remaining media into the filter unit and continue filtering.    -   After all the media has been filtered, disconnect the vacuum        hose from the vacuum filter unit and turn off the vacuum pump.        Remove the receiver portion of the filter unit from the filter        bottle. Place a new sterile bottle cap on the bottle.    -   Store at 2° C. to 10° C. Protect from light.        Initial Hybridoma Cell Culture    -   Thaw vial of stock hybridoma frozen culture in a pre-warmed        37° C. H₂O bath.    -   Spray the outside of the freeze vial with 70% ethanol.    -   Move the thawed vial into the Biological Safety Cabinet.    -   Remove the cells from the freeze vial and transfer the cells to        a 15 ml centrifuge tube.    -   Add 7 ml of cell culture media drop-wise to the 15 ml centrifuge        tube containing the thawed cells.    -   Centrifuge the 15 ml centrifuge tube containing the thawed cells        and culture media for 5 minutes at 200 g force.    -   While the cells are in the centrifuge, add 45 ml of cell culture        media to a sterile T-225 flask.    -   After centrifugation, visually inspect the tube for the presence        of a cell pellet.    -   Remove the media from the centrifuge tube being careful not to        dislodge the cell pellet. Note: If the cell pellet is disturbed,        repeat the centrifugation step.    -   Add 5 ml of cell culture media to the 15 ml centrifuge tube        containing the pelleted cells. Pipette to re-suspend the cell        pellet into the media.    -   Transfer the entire contents of the resuspended cells and        culture media into the T-225 flask containing the 45 ml of        media.    -   Cap the T-225 flask.    -   Observe for presence of intact cells under the microscope. Place        the T-225 flask immediately into a CO2 incubator and allow the        cells to incubate overnight.        Expansion of Hybridoma Cell Line    -   Continue to monitor the cell culture for viability,        concentration, and presence of contamination.    -   Monitor and adjust the cell suspension from the initial T-225        flask until the concentration is approximately 600,000 cells/ml        to 800,000 cells/ml and a total of 200 to 250 ml of media.    -   Dislodge cells and add additional media as needed to meet        minimum cell density requirements. Divide and transfer cell        suspension into one new sterile T-225 flask. Place the 2×T-225        flasks into the CO2 incubator.    -   Monitor the cells from the 2×T-225 flasks until the        concentration is approximately 600,000 cells/ml to 800,000        cells/ml, and a total of between 200 to 250 ml of media for each        flask.    -   Dislodge cells and add additional media as needed to meet        minimum cell density requirements. Divide and transfer the cell        suspensions into 2 additional new sterile T-225 flasks for a        total of 4×T-225 flasks. Return all flasks to the CO2 incubator.    -   Monitor the cells, and adjust volume in the 4×T-225 flasks until        the cell concentration is approximately 600,000 cells/ml to        800,000 cells/ml with a total volume of approximately 250 ml per        T-225 flask (or approximately 1000 ml total).    -   Continue to monitor the cells from the 4×T-225 flasks until the        cells have grown to exhaustion, with a final viability of        0%-15%. The cell culture supernatant is now ready for the        Clarification Process.        Clarification of Supernatant    -   Turn on the tabletop centrifuge. Place the 500 ml tube adapters        into the rotor buckets, close the lid and set the temperature to        4° C. (+/−) 4° C.    -   Using aseptic technique, pour the media from all four of the now        exhausted T-225 flasks into 2×500 ml conical centrifuge tubes.    -   Make sure the 2×500 ml tubes are balanced. Transfer supernatant        from one tube to the other as necessary to balance them.    -   Centrifuge the exhausted supernatant at 1350 g (+/−40 g) for 15        minutes at 2° C. to 10° C.    -   After centrifugation is complete, aseptically decant the        supernatant into a sterile 1000 ml storage bottle and secure        with a sterile cap.    -   Aseptically transfer 1 ml to the microfuge tube. Store microfuge        tube with sample at 2° C. to 10° C. (Protect from light).    -   The clarified supernatant sample is ready for IgG evaluation        using the Easy-Titer® Assay.        Buffer Preparation        Binding Buffer:    -   Add approximately 600 ml of DI H₂O to a clean beaker.    -   Add 77.28 ml of Boric Acid solution (4% W/V). Stir at room        temperature with a clean stir bar.    -   Weigh out 233.76 g of Sodium Chloride and place into the        solution while continuing to stir.    -   Bring solution up to approximately 950 ml with DI H₂O and        continue to stir.    -   When the Sodium Chloride has dissolved and the solution is        clear, adjust the pH to 9.0±0.2 with Sodium Hydroxide.    -   Remove the solution to a clean 1000 ml graduated cylinder and QS        to 1000 ml with DI H₂O.    -   Transfer the completed buffer to an appropriate storage bottle.        This buffer may be stored for up to 7 days before use.    -   Repeat this entire process to prepare an additional 0.2 liters        to 1.0 liter of Binding Buffer.        Elution Buffer    -   Weigh out 1.725 g of sodium phosphate, monobasic and place into        a clean 250 ml beaker with a clean stir bar.    -   Weigh out 3.676 g of sodium citrate and place into the same        clean 250 ml beaker.    -   Add approximately 175 ml of DI H₂O and stir at room temperature        until dissolved.    -   Weigh out 4.38 g of Sodium Chloride and place into the solution        while continuing to stir.    -   Bring solution up to approximately 225 ml with DI H₂O and        continue to stir.    -   When the Sodium Chloride has dissolved and the solution is        clear, adjust the pH to 3.5±0.2 with Hydrochloric Acid.    -   Remove the solution to a clean 250 ml graduated cylinder and QS        to 250 ml with DI H₂O.    -   Connect a 500 ml sterile acetate vacuum filter unit (0.2 μm) to        a vacuum pump system and filter sterilize the solution.    -   Remove the filter and close the container with a sterile cap.        Antibody Adsorption    -   Pour the Clarified Supernatant (˜1 L) into a clean 4000 ml        plastic beaker with a clean stir bar.    -   Add an approximately equal amount (˜1 L) of the Binding Buffer        to the clean 4000 ml plastic beaker containing the clarified        supernatant. Add a clean stir bar.    -   Cover the beaker with clean plastic wrap and label “Antibody        Binding.”    -   Calculate the approximate amount of STREAMLINE® Protein A that        will be needed using the data in Table 1.

TABLE 1 Volume of Protein A Resin Required Volume of Protein A QuantityIgG (μg/ml) Resin Required in in Supernatant Milliliters (ml) >180-≦20012.0 >160-≦180 11.0 >140-≦160 10.0 >120-≦140 9.0 >100-≦120 8.0  >80-≦1007.0 >60-≦80 6.0 >40-≦60 4.5 >20-≦40 3.5 ≦20 2.0

-   -   Secure a clean Disposable Column and stopcock assembly to a ring        stand and clamp. Close the stopcock.    -   Mix appropriate amount of STREAMLINE Protein A beads by        inverting the bottle several times. Withdraw the required volume        and place into the Disposable Column.    -   Wash the STREAMLINE Protein A beads with 10 ml of DI H₂O. Open        the stopcock and allow the DI H₂O to drain. Close the stopcock.        Repeat with an additional 10 ml of DI H₂O.    -   Wash the STREAMLINE Protein A beads with 10 ml of Binding        Buffer. Open the stopcock and allow the Binding Buffer to drain.        Close the stopcock. Repeat with an additional 10 ml of Binding        Buffer.    -   Resuspend the STREAMLINE Protein A beads in ˜10 ml of the        Clarified Supernatant and Binding Buffer solution (from the 4000        ml beaker) and transfer the beads into the 4000 ml beaker        containing the Clarified Supernatant and Binding Buffer        solution. Repeat as required to transfer any remaining beads.        When completed, discard the column and stopcock.    -   Allow the mixture to mix vigorously at 2° C. to 10° C. for        approximately 18 hours.    -   When mixing is complete, turn off the stir plate and remove the        “Antibody Binding” beaker with the buffered supernatant and bead        suspension back to the lab bench area. Allow the STREAMLINE        Protein A beads to settle to the bottom of the beaker        (approximately 5 minutes).    -   Secure a clean Disposable Column and stopcock assembly to a ring        stand and clamp. Close the stopcock.    -   Label a clean, 250 ml bottle or suitable container “Column        Wash-Post Binding.”    -   Label a clean plastic beaker “Supernatant-Post Binding.”    -   Decant the supernatant from the 4000 ml beaker into the clean,        labeled, 2 liter plastic beaker, leaving the beads in the bottom        of the 4000 ml beaker. Cover the 2000 ml beaker containing the        “Supernatant-Post Binding” solution with clean plastic wrap and        store at 2° C. to 10° C.    -   Add approximately 15 ml of Binding Buffer into the decanted 4000        ml “Antibody Binding” beaker. Resuspend the STREAMLINE Protein A        beads and transfer them to the column. Open the stopcock and        allow the Binding Buffer to drain into the “Column Wash-Post        binding” container. Close the stopcock when drained.    -   Transfer any remaining STREAMLINE Protein A beads in the        “Antibody Binding” beaker by adding additional Binding Buffer,        mixing, and transferring to the column as in the preceding        steps. Close the stopcock when drained.    -   Calculate the approximate amount of Binding Buffer needed to        wash the STREAMLINE Protein A beads in the column using the data        in Table 2.

TABLE 2 Binding Buffer Volume for Column Wash Volume of Binding QuantityIgG (μg/ml) Buffer Required in in Supernatant Milliliters (ml) >180-≦2005 column washes total with 15.0 ml each >160-≦180 5 column washes totalwith 15.0 ml each >140-≦160 5 column washes total with 12.5 mleach >120-≦140 5 column washes total with 12.5 ml each >100-≦120 5column washes total with 12.5 ml each >80-≦100 5 column washes totalwith 10.0 ml each >60-≦80 5 column washes total with 10.0 mleach >40-≦60 5 column washes total with 7.5 ml each >20-≦40 5 columnwashes total with 5.0 ml each ≦20 5 column washes total with 5.0 ml each

-   -   Wash the STREAMLINE Protein A beads in the column with the        appropriate volume of Binding Buffer for the appropriate number        of washes, continuing to collect the efluent into the “Column        Wash-Post Binding” container.    -   When completed, close the stopcock. Store the “Column Wash-Post        Binding” container at 2° C. to 10° C.    -   Determine the Total Volumes of Elution Buffer and Neutralization        Buffer needed to elute the STREAMLINE Protein A beads in the        column from Table 3.

TABLE 3 Determination of Amount of Elution Buffer and NeutralizationBuffer Total Volume of Volume of Total Volume of Neutralization ElutionVolume of Elution Buffer Quantity IgG Buffer Neutralization BufferRequired (μg/ml) in Required Buffer Required per per fractionSupernatant (ml) Required (ml) fraction (ml) (ml) >180-≦200 72 7.2 121.2 >160-≦180 66 6.6 11 1.1 >140-≦160 60 6.0 10 1.0 >120-≦140 54 5.4 90.9 >100-≦120 48 4.8 8 0.8  >80-≦100 42 4.2 7 0.7 >60-≦80 36 3.6 60.6 >40-≦60 27 2.7 4.5 0.45 >20-≦40 21 2.1 3.5 0.35 ≦20 12 1.2 2 0.2

-   -   Label 9 sterile conical centrifuge tubes “Eluted Antibody”,        Fraction # (1 through 9).    -   Place the appropriate volume of Neutralization Buffer required        per fraction (as determined from Table “C” above) into each of        the 9 “Eluted Antibody” fraction tubes and place securely under        the column stopcock outlet.    -   Elute the STREAMLINE Protein A beads in the column fraction by        fraction with the appropriate volume of Elution Buffer required        per fraction (as determined from Table 3 above) while collecting        the eluate into each of the “Eluted Antibody” tubes containing        Neutralization Buffer.    -   When the elutions are complete, mix each “Eluted Antibody”        fraction tube gently by swirling several times. Remove        approximately 50 μl of fraction # 3 and place on a pH test paper        strip to ensure that the eluate has been neutralized to an        approximate pH between 6.5 to 8.5. If required, add additional        Neutralizing Buffer or Elution Buffer as needed to bring pH into        range.    -   When pH evaluation is completed, perform an Absorbance Scan of a        sample from each fraction at 280 nm-400 nm to determine the        approximate concentration of IgG in the eluate prior to        proceeding to the Dialysis Process.        -   Accept fractions as part of the Eluate Pool if the A280-A400            value is ≧0.200.        -   Reject fractions as part of the Eluate Pool if the A280-A400            value is <0.200.    -   Label a sterile conical centrifuge tube “Eluted Antibody,”        “Eluate Pool,” and combine all fractions that were Accepted as        part of the pool.    -   Perform an Absorbance Scan of a sample of the Eluate Pool to        determine the approximate concentration of IgG in the eluate        prior to proceeding to the Dialysis Process.    -   Estimate the volume of the Eluate Pool and calculate the        approximate total mgs of IgG.    -   Volume of Eluate Pool: ______mls×______IgG mg/ml=______Total mgs        of IgG        Antibody Dialysis    -   Remove the “Eluted Antibody” tube from 2° C. to 10° C.    -   Calculate the approximate length of Dialysis Tubing that will be        needed to dialyze the antibody eluate using the approximate        volume of eluate and the data in Table 4.

TABLE 4 Calculation of Length of Dialysis Tubing Needed ApproximateLength Approximate Approximate Needed for Length Approximate ApproximateVolume/length Length Needed Head Space Sample plus Needed for TotalLength of Volume of Ratio of Dialysis for Eluent of 20% Headspace TieOff of Dialysis Tubing Eluent (ml) Tubing Sample (cm) (cm) (cm) Tubing(cm) Needed (cm) 39.6 2 20 4 24 15 63 36.3 2 18 4 22 15 59 33.0 2 17 320 15 55 29.7 2 15 3 18 15 51 26.4 2 13 3 16 15 47 23.1 2 12 2 14 15 4319.8 2 10 2 12 15 39 14.85 2 7 1 9 15 33 11.55 2 6 1 7 15 29 6.6 2 3 1 415 23

-   -   Cut the appropriate length of dialysis tubing required.        SPECTRA/POR® 2Regenerated Cellulose Membrane, 12,000-14,000        Dalton Molecular Weight Cutoff (MWCO), 16 mm Diameter, Spectrum        Laboratories Inc., Cat. No. 132678).    -   Hydrate the dialysis membrane tubing in 1000 ml of DIH₂O for >30        minutes.    -   Calculate the approximate volume of Dialysis Buffer needed to        dialyze the antibody eluate using the data in Table 5.

TABLE 5 Volume of Dialysis Buffer Required Length of Quantity IgG FinalVolume of Dialysis Volume of Dialysis (μg/ml) in Eluted Antibody inTubing Needed Buffer (1 × PBS) Supernatant Milliliters (ml) (cm) Neededin Liters >180-≦200 39.6 ml 63 cm 3 complete changes of 4.0Liters >160-≦180 36.3 ml 59 cm 3 complete changes of 3.6Liters >140-≦160 33.0 ml 55 cm 3 complete changes of 3.3Liters >120-≦140 29.7 ml 51 cm 3 complete changes of 3.0Liters >100-≦120 26.4 ml 47 cm 3 complete changes of 2.6 Liters >80-≦100 23.1 ml 43 cm 3 complete changes of 2.3 Liters >60-≦80 19.8 ml39 cm 3 complete changes of 1.9 Liters >40-≦60 14.85 ml  33 cm 3complete changes of 1.5 Liters >20-≦40 11.55 ml  29 cm 3 completechanges of 1.2 Liters ≦20  6.6 ml 23 cm 3 complete changes of 0.7 Liters

-   -   Place the appropriate amount of Dialysis Buffer into a suitable        sized plastic beaker. Label the beaker “Dialyzed Antibody.” Add        a clean stir bar and place the beaker on a stir plate inside a        refrigerator or cold room at 2° C. to 10° C.    -   Rinse the dialysis tubing thoroughly in DI—H₂O. Tie two end        knots approximately 7 cm from one end of the dialysis tubing and        secure tightly.    -   Add approximately 5 ml of DI—H₂O into the dialysis tubing.    -   Fill the dialysis tubing with the eluted antibody from the        “Eluted Antibody” collection tube.    -   Tie two end knots approximately 7 cm from the remaining open end        of the dialysis tubing and secure tightly. Ensure that the        headspace is approximately that as derived from Table 4.    -   Place the filled and closed dialysis tubing into the dialysis        reservoir with the appropriate volume of 1×PBS (from Table 5).    -   Cover the beaker with clean plastic wrap. Adjust the speed on        the stir plate such that the dialysis sample spins freely, but        is not pulled down into the vortex of the dialysate. Dialysis        should take place at 2° C. to 10° C. with 3 buffer exchanges in        total within a 24 hour period.        Antibody Filtration    -   Label a sterile collection tube “Dialyzed Antibody.”    -   Remove the dialyzed sample tubing from the dialysis beaker. Cut        the dialysis tubing open at one end and transfer the dialyzed        sample into the “Dialyzed Antibody” centrifuge tube.    -   Label another sterile collection tube “Dialyzed Antibody.”    -   Select a sterile Luer Lok syringe with adequate capacity to hold        the final dialyszed volume.    -   Attach an Acrodisc® Syringe Filter to the opening of the syringe        (0.2 μm HT Tuffryn® Membrane, Low Protein binding, Gelman        Laboratories, Cat. No. 4192). Remove the plunger from the        syringe and while holding the syringe upright, transfer the        dialyszed monoclonal antibody from the “Dialyzed Antibody” tube        into the syringe. Replace the plunger.    -   Hold the Acrodisc® Syringe Filter over the opened, sterile,        labeled “Purified Antibody” collection tube, and depress the        syringe plunger to filter the purified antibody into the        “Purified Antibody” tube.    -   When filtration is complete, cap the “Purified Antibody” tube        and store at 2° C. to 10° C.    -   Determine concentration of purified monoclonal antibody using        A280 procedure.

Example 4 General Method for Epitope Mapping

General Approach

Epitope mapping is performed to identify the linear amino acid sequencewithin an antigenic protein (i.e., the epitope) that is recognized by aparticular monoclonal antibody. A general approach for epitope mappingrequires the expression of the full-length protein, as well as variousfragments (i.e., truncated forms) of the protein, generally in aheterologous expression system. These various recombinant proteins arethen used to determine if the specific monoclonal antibody is capable ofbinding one or more of the truncated forms of the target protein.Through the use of reiterative truncation and the generation ofrecombinant proteins with overlapping amino acid regions, it is possibleto identify the region that is recognized by the monoclonal antibodyunder investigation. Western blot analysis or ELISA is employed todetermine if the specific monoclonal antibody under investigation iscapable of binding one or more of the recombinant protein fragments.This approach can ultimately identify the peptide regions that containsthe epitope and, in some cases, to refine the epitope precisely to an8-15 amino acid sequence. An epitope can be a continuous linear sequenceof 8-15 amino acids or it can be discontinuous with the antibody bindingto a site on the protein composed of different sections of the peptidechain. Discontinuous epitopes generally cannot be mapped.

Construct Design and Creation

The first step in epitope mapping is the design of nested genetruncations. Frequently, the gene is divided into four equal parts forfurther analysis.

Gene Cloning Strategy

The general cloning strategy begins with PCR-based generation of thecloned gene fragments. In order to efficiently express the clonedfragment, especially when using small amino acid regions, the clonedfragment is expressed as a fusion protein, i.e. fused to another carrierprotein that is stably expressed in the system. Green fluorescentprotein (GFP) is frequently used as the carrier protein. GFP is includedas a fusion partner to stabilize the truncation fragments and improveexpression during the subsequent in vitro protein expression step. GFPalso permits the tracking of fusion-protein expression using anti-GFPantibodies.

Cloning to create the GFP-protein construct is performed using eitherthe mega-priming approach or through the use of plasmid cloning into thepScreen-GFP vector. Generally, the truncation fragments are fused to GFPand control sequences necessary for protein expression using a techniquecalled megapriming.

Megapriming is the joining of two or more DNA fragments by annealinghomologous regions at the end of the respective fragments and extendingthe annealed single-stranded DNA with a thermostable DNA polymerase.This process creates one large DNA fragment from two or more smallerfragments, linking them by their shared sequence. This large fragment isthen amplified using standard PCR.

If megapriming cannot be used successfully, the truncation fragments canbe cloned into a plasmid containing GFP and protein-expression controlsequences. This cloning creates the GFP/fragment fusions necessary forepitope mapping. The remainder of the protocol can then proceed asdescribed below.

Protein Expression

The expression constructs created by, for example, megapriming are thenintroduced into the Rapid Translation System (RTS). RTS is a cell-freeprotein expression system derived from E. coli lysates. This systempermits rapid (3-4 hour) expression of proteins from DNA templates.

If RTS does not produce adequate levels of protein expression, then thetruncation fragments will be cloned into the GFP protein-expressionplasmid. These fusion plasmids are then transformed into an E. colistrain optimized for protein expression. Protein expression is inducedin a growing culture of bacteria and, following outgrowth, the cells arelysed. The proteins in the complex cell lysate are then separated bypolyacrylamide gel electrophoresis (PAGE), and the remainder of theprotocol is the same as below.

Protein Detection and Epitope Mapping

Protein fragments produced by RTS are separated using PAGE andtransferred onto nitrocellulose membranes. The membrane-bound proteinsare then exposed to the antibody under investigation in solution.Antibody/protein binding is identified using colorimetric techniquesknown in the art.

Antibody binding of the full-length protein and some subset of thetruncated protein fragments constitutes a positive result. If theabsence of a particular section of the protein eliminates antibodybinding, then the epitope lies on this fragment.

If the antibody to be mapped does not recognize protein bound tonitrocellulose membranes, then alternative methods for detectingantibody/protein interactions, such as, for example, ELISA orimmunoprecipitation are used. Methods for detecting antibody/proteininteractions are well known in the art.

Refining the Epitope Location

Since the above-described protocol will only narrow the location of theepitope down to approximately one-quarter of the protein, it isnecessary to repeat the process on the quarter of the protein determinedto contain the epitope in order to further resolve the location of theepitope. For a very large protein, it may be necessary to repeat thisprocess two to three times to narrow the epitope down to 8-15 aminoacids.

Example 5 Characterization of Epitope for MCM6 Monoclonal Antibody 9D4.3

Epitope mapping for MCM6 monoclonal antibody 9D4.3 was carried outessentially as described above in Example 4. Specifically, PCR was usedto create four MCM6 gene truncations of the full-length MCM6 protein,followed by RTS to generate recombinant MCM6 protein fragments as GFPfusion proteins, and finally western blotting to detect antibody bindingto specific MCM6 fragments. GFP was joined with the MCM6 genetruncations in a second round of PCR to ensure robust and stableexpression in RTS.

The MCM6 protein fragments were analyzed by western blotting to identifyfragment(s) that bind the 9D4.3 antibody. The western blot was probeddirectly with the 9D4.3 monoclonal antibody and a GFP antibody. Apositive band was detected with the MCM6 truncation product designatedas fragment 4. Fragment 4 was divided into five smaller fragments andthe above process repeated to narrow the epitope.

The second set of MCM6 protein fragments was also analyzed by westernblotting to identify fragment(s) that bind the 9D4.3 antibody. Thewestern blot was probed directly with the 9D4.3 monoclonal antibody anda GFP antibody. Monoclonal antibody 9D4.3 was shown to bind to theregion of MCM6 designated as 4-4. This fragment was again divided intosix smaller fragments and the above process repeated to narrow theepitope.

The MCM6 protein fragments were again analyzed by western blotting asbefore. The western blot was probed directly with the 9D4.3 monoclonalantibody and a GFP antibody. A positive band was detected with the MCM6fragment designated as 4-4-1. Additional fragments were generated tonarrow the epitope region. Western blot analysis indicated that theepitope for the MCM6 antibody 9D4.3 comprises the amino acid sequenceIDSEEELINKKRI (SEQ ID NO:5).

Results

Initial results showed that the epitope for the MCM6 monoclonal antibody9D4.3 is located within the C-terminal region of the MCM6 protein.Continued truncations of the MCM6 protein showed that the epitoperecognized by 9D4.3 is located within a thirteen amino acid region,specifically corresponding to amino acid residues 760-772 of SEQ ID NO:3(IDSEEELINKKRI (SEQ ID NO:5)). Additional rounds of RTS may be able torefine the epitope location further.

Example 6 Characterization of Epitope for MCM7 Monoclonal Antibody 2E6.2

Epitope mapping for MCM7 monoclonal antibody 2E6.2 was performedessentially as described above in Example 5. The full-length MCM7 genesequence (SEQ ID NO:1) was used as the starting sequence for designinggene fragments.

Results

The epitope for MCM7 monoclonal antibody 2E6.2 was determined to belocated within the protein region comprising amino acid residues 127-138of SEQ ID NO:1 (PAELMRRFELYF (SEQ ID NO:6)). Additional rounds of RTSmay be able to refine the epitope location further.

1. A monoclonal antibody that is capable of specifically binding toMCM7, wherein the antibody is selected from the group consisting of: (a)the monoclonal antibody produced by the hybridoma cell line 2E6.2,deposited with the ATCC as Patent Deposit No. PTA-6669; (b) a monoclonalantibody that binds to an MCM7 epitope consisting of the amino acidsequence of SEQ ID NO:6; and (c) an antigen binding fragment of amonoclonal antibody of (a) or (b), wherein the fragment retains thecapability of specifically binding to MCM7.
 2. The hybridoma cell line2E6.2, deposited with the ATCC as Patent Deposit No. PTA-6669.
 3. Ahybridoma cell line capable of producing a monoclonal antibody of claim1(a) or claim 1(b).
 4. A kit for diagnosing high-grade cervical diseasecomprising at least one monoclonal antibody or an antigen bindingfragment according to claim
 1. 5. The kit of claim 4, wherein themonoclonal antibody is the monoclonal antibody produced by the hybridomacell line 2E6.2, deposited with the ATCC as Patent Deposit No. PTA-6669.6. The kit according to claim 4, wherein said kit further comprises aperoxidase blocking reagent, a protein blocking reagent, chemicals forthe detection of antibody binding to a biomarker protein, acounterstain, a bluing agent, and instructions for diagnosing high-gradecervical disease.
 7. The kit according to claim 4 further comprisingreagents for Papanicolaou (Pap) staining.